Experts assess the state of in-development radiation drugs

07/1/2012 | Chemical & Engineering News

The FDA launched its medical countermeasures program in 2010 to address growing concerns about radiation exposure, but success is still far off. None of the 30 licensed drugs and clinical-stage candidates for radiation syndromes is far advanced, according to the NIH. Federal agencies encourage repurposing currently used drugs for treatment of acute radiation syndrome. The NIH plans to broaden efforts to encourage more small and large drug companies to focus on radiation drugs.

View Full Article in:

Chemical & Engineering News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations